EX-99.1 2 clb-ex991_6.htm EX-99.1 clb-ex991_6.htm

Exhibit 99.1

 

 

 

FOR IMMEDIATE RELEASE

 

CORE LAB REPORTS SECOND QUARTER 2019 RESULTS FROM CONTINUING OPERATIONS:

 

GAAP EPS OF $0.43; $0.46, EX-ITEMS

 

RESERVOIR DESCRIPTION INTERNATIONAL REVENUE UP 8% YEAR-OVER-YEAR

 

RESERVOIR DESCRIPTION OPERATING MARGINS OF 15%, EX-ITEMS, OF 17%, UP 360 BPS SEQUENTIALLY AND UP 270 BPS YEAR-OVER-YEAR

 

RESERVOIR DESCRIPTION SEQUENTIAL AND YEAR-OVER-YEAR INCREMENTAL MARGINS EXCEEDED 60%, EX-ITEMS

 

PRODUCTION ENHANCEMENT U.S. ENERGETIC PRODUCT SALES UP OVER 18% SEQUENTIALLY, OUTPACING U.S. COMPLETIONS UP 8%

 

COMPANY POSTS OILFIELD SERVICE-LEADING ROIC OF 21.3%

AMSTERDAM (24 July 2019) - Core Laboratories N.V. (NYSE: "CLB US" and Euronext Amsterdam: "CLB NA") ("Core", "Core Lab", or the "Company") reported that continuing operations resulted in second quarter 2019 revenue of $169,000,000. Second quarter 2019 revenue was impacted by a mid-quarter divestment of a non-strategic business in Asia Pacific and a softer than expected North American services market.  Core’s operating income was $28,000,000 with earnings per diluted share ("EPS") of $0.43, all in accordance with U.S. generally accepted accounting principles ("GAAP"); operating income, ex-items, a non-GAAP financial measure, was $29,600,000, yielding operating margins of 17.5% and EPS, ex-items, was $0.46.  A full reconciliation of non-GAAP financial measures is included in the attached financial tables.

Core’s Board of Supervisory Directors ("Board") and the Company’s Executive Management continue to focus on strategies that maximize return on invested capital ("ROIC") and free cash flow ("FCF"), a non-GAAP financial measure defined as cash from operations less capital expenditures, factors that have high correlation with maximizing total shareholder return. Core’s asset-light business model and capital discipline promote capital efficiency designed to produce more predictable and superior long-term ROIC.  Bloomberg's calculations using the latest comparable data available indicate that Core’s ROIC of 21.3% is the highest of the oilfield service companies listed as Core’s Comp Group by Bloomberg.

 

 

 

 

 


 

Segment Highlights

Core Laboratories reports results under two operating segments:  Reservoir Description and Production Enhancement.  During the second quarter of 2019, directly tied to the Company’s on-going efforts to streamline operating structures and business reporting lines, Core developed a cost reduction plan and recognized associated costs of $3,000,000, which are included in Core’s ex-items.  This plan is to ensure Core Lab is positioned to perform at maximum efficiency and for potential changes in North American market conditions.

Reservoir Description

Reservoir Description revenue in the second quarter of 2019 was $105,600,000, up over 2% sequentially and up 3% year-over-year, with international revenue up 8% year-over-year.  The mid-quarter divestment of a non-strategic business reduced projected quarterly revenue by approximately $2,000,000, but yielded a modest net addition to earnings and operating margins.  Operating income on a GAAP basis was $15,900,000, while operating income, ex-items, was $18,200,000, up 30% sequentially and 23% year-over-year, yielding year-over-year incremental margins over 60% and operating margins, ex-items, of 17%, up 360 basis points, sequentially.

Reservoir Description operations are heavily exposed to international and offshore activity levels.  More than 80% of its revenue is sourced outside the U.S., where core, reservoir fluid and derived product samples originate from international projects.  Improvement in year-over-year and sequential financial performance in Reservoir Description is a result of increased international and offshore client activity.  Core conducted services for both newly developed fields and brownfield extensions in offshore areas such as: Australia, Brazil, Guyana, Mexico, the Middle East, and the North Sea.  These analytical programs provide accurate, comprehensive datasets of rock and hydrocarbon properties that are critical for optimizing reservoir development.  

In the second quarter of 2019, Core Laboratories, under the direction of Talos Energy (“Talos”), continued to provide wellsite and laboratory services for the Zama Project, located in Mexico’s Block 7 in the Sureste Basin, Gulf of Mexico.  This program included core stabilization and the initial stages of laboratory analysis on conventional core from a second well in this offshore Mexico project, the Zama-3DEL delineation well.  Over 700 feet of conventional core was captured, with 99% recovery, breaking Talos’ own record for the longest conventional core from a single well in the history of offshore Mexico.  Previously established workflows developed by Core Laboratories for a wide range of sandstone reservoirs in the U.S. Gulf of Mexico were again successfully applied.  

Advanced laboratory analysis continues on conventional core from the Zama-2DEL ST-01 well and will be integrated with the analytical results from the Zama-3DEL conventional core. Talos will use the data sets provided by Core Laboratories to calibrate models that will ultimately provide reliable calculations of recoverable resources.  Timothy S. Duncan, Talos’ President and Chief Executive Officer, said in a news release, "based on the preliminary results of our appraisal program, we have confirmed the combination of outstanding subsurface properties, significant recoverable volumes, and attractive economic potential that have already made Zama a globally-recognized asset.”  Core Laboratories is pleased to continue to be part of this unprecedented exploration achievement and looks forward to completing detailed geoscience and engineering studies.

 

 


 

During the second quarter of 2019, opportunities continued to emerge in Brazil. Core completed a fully integrated, multi-disciplinary study of Brazil’s North Eastern Offshore Basin. This comprehensive, multi-client, interpretive study and dataset compilation incorporates: stratigraphy, geochemistry, reservoir geology and seal rock analysis across the Jequitinhonha, Almada, Camamu and Sergipe-Alagoas Atlantic Margin Basins. This study provides the participating companies access to a rock-based, subsurface dataset to evaluate new opportunities, including the deepwater Late Cretaceous turbidite plays in the Sergipe-Alagoas Basin.

Production Enhancement

Production Enhancement operations, largely focused on complex completions in unconventional tight-oil reservoirs in the U.S. and conventional offshore development projects, posted second quarter 2019 revenue of $63,400,000; down 4% sequentially, due to a decline in discretionary service-related revenue.  Production Enhancement’s U.S. energetic product revenue was up 18% sequentially, which substantially outpaced U.S. completion activity, up 8%, due to demand for Core’s high-end perforating system energetics.  The segment’s GAAP operating income was $10,400,000, while operating income, ex-items, was $11,600,000, which yielded operating margins, ex-items, of 18%.  

During the second quarter of 2019, Core’s Production Enhancement segment commissioned Core’s new, cutting-edge, Reservoir Optimized Completions Lab (“ROC LabTM”) in Godley, Texas. The ROC LabTM is designed to determine the best energetic solutions for a specific rock type, to maximize productivity of an operator’s reservoir.  The ROC LabTM features an industry-leading, Ultra High Pressure/High Temperature perforation test vessel. The test vessel is paired with a proprietary flow system that uses highly specialized, internally developed and manufactured pumps and flow controllers.  Combined, these technologies create a proprietary flow loop capable of dynamically displacing oil, brine, and gas through rock samples that have been perforated with preselected energetics.  Core relied on its multi-decadal expertise in conducting multi-phase fluid flow tests through porous medium to optimize this technological investment.  

Perforating designs can be tested in the ROC LabTM, while replicating downhole reservoir stresses, such as temperature, pressure, and underbalance/overbalance conditions. The ROC LabTM is a collaborative development between the ballistics experts in Production Enhancement and the scientists in Core’s Reservoir Description rock, fluid, and laboratory instrumentation segments.   This collaboration presents clients with the opportunity to obtain measured data on the interrelationships of rocks, pore fluids, and various energetic options, all at reservoir stress conditions. On-site, high-resolution industrial, 3D-CT capabilities give clients the ability to view inside the cored samples to see depth of penetration, determine tunnel volume and geometry, and assess possible completion damage to the formation, all with industry-leading imaging resolution.  Combined with Core’s proprietary geological analysis techniques, Core’s clients can now select and test energetics that will optimize performance in specific stratigraphic targets.  Core is uniquely capable of bringing together its ballistics expertise, vast geological and flow studies knowledge, laboratory instrumentation manufacturing and digital imaging technologies to provide this service.

Core’s Ballistic Delivery System™ (“BDS”) and the Addressable Fire SwitchTM (“AFS”) are key differentiators of Core’s pre-assembled GoGunTM Adaptive Perforating System. During the second quarter of 2019, Core’s client adoption of these technologies continued to grow with the conversion from legacy communication devices to this industry-leading, advanced delivery system.

 


 

Core’s Production Enhancement team remains focused on systemizing and de-risking the deployment of perforating systems through quarterly expansion of the BDS and pre-assembled GoGun™, both of which reduce operating costs and increase reliability for Core’s clients

Free Cash Flow, Dividends and Share Repurchases

During the second quarter of 2019, Core continued to generate FCF, with cash from operations of $17,100,000 and capital expenditures of $7,000,000, yielding FCF of $10,100,000. The FCF yield for the second quarter of 2019 was lower than in the first quarter of 2019 partially due to investment in technological innovations and automation programs, such as for GoGunTM and ROC LabTM.  

The second quarter of 2019 also marks the 71st consecutive quarter that the Company generated positive FCF.  Core’s second quarter 2019 free cash was returned to Core’s shareholders via the Company’s regular quarterly dividend.  Additionally, the Company completed the divestment of two non-strategic businesses that were no longer critical for Core’s future growth, with total proceeds of $19,600,000. Surplus proceeds from the sales were used to reduce outstanding debt by $5,000,000 under the Company’s revolving credit facility.  Core will continue its commitment to invest for future growth of the Company and will return FCF generated to shareholders via the Company’s regular quarterly dividend and future opportunistic share repurchases.  

On 16 April 2019, the Board announced a quarterly cash dividend of $0.55 per share of common stock, which was paid on 21 May 2019 to shareholders of record on 26 April 2019. Dutch withholding tax was deducted from the dividend at a rate of 15%.

On 12 July 2019, the Board announced a quarterly cash dividend of $0.55 per share of common stock, payable in the third quarter of 2019. The quarterly cash dividend will be payable on 12 August 2019 to shareholders of record on 22 July 2019. Dutch withholding tax will be deducted from the dividend at a rate of 15%.

Return On Invested Capital

Core Lab's ROIC of 21.3% is the highest of the peer group compiled and reported by Bloomberg.  The Company's Board has established an internal performance metric of achieving a leading relative ROIC performance compared with the oilfield service companies listed as Core's Comp Group by Bloomberg. The Company and its Board believe that ROIC is a leading long-term performance metric used by shareholders to determine the relative investment value of publicly traded companies. Further, the Company and its Board believe that shareholders will benefit if Core consistently performs at high levels of ROIC relative to its Comp Group.  

According to the latest Comp Group financial information from Bloomberg, Core's ROIC is the highest of any comparably-sized oilfield service company (greater than $2 billion market capitalization). Comp Group companies listed by Bloomberg include:  Halliburton, Schlumberger, National Oilwell Varco, Baker Hughes GE, TGS-NOPEC Geophysical Company, and Wood (formerly known as “The Wood Group”), among others.  Core Lab is one of only three of the 14 companies listed in the Comp Group posting ROIC that exceeded their Weighted Average Cost of Capital (“WACC”).  Core’s ratio of ROIC to WACC is the highest of any company in the Comp Group.

 

 


 

Third Quarter 2019 Revenue and EPS Guidance

During the first half of 2019, the global crude-oil market stabilized with the continuation of OPEC production cuts and a modest decline in global crude-oil inventories, supporting a balance between supply and demand.  The most recent International Energy Agency report estimates demand growth for 2019 will be 1.1 million barrels per day, slightly down from the first quarter of 2019. Also, during the second quarter of 2019, the international offshore rig count increased by 26%, year-over-year, and the overall international rig count increased by 14.5% year-over-year. While market concerns exist regarding the balance of future crude-oil supply and demand, crude-oil production additions are limited on a global basis. The decline curve is prevailing in the mature crude-oil fields internationally, heading toward a supply gap over time.

These crude-oil market fundamentals drive Core’s clients’ international activity levels, which are expected to continue to improve in the third quarter of 2019.  The balancing of crude oil supply and demand supports the crude oil price which underpins the Final Investment Decisions and emerging international crude oil field reinvestments.  These international investments are critical, as the decline in production from mature fields continues and new field development is required for supply replacement.  Consequently, Core’s Reservoir Description segment expects to benefit from increased client spending in the international crude oil markets.

The average third quarter 2019 U.S. rig count is projected to be down.  While operators continue to focus on generating FCF and returns on investment, optimizing well completions remain a significant lever in growing field investment returns while managing within their capital budgets.  As a result, Core projects U.S. onshore completion activity to be flat sequentially.  Core would expect U.S. energetic sales to exceed the rate of completion activity, as they did in the second quarter of 2019.

Therefore, Core expects consolidated third quarter 2019 revenue of approximately $171,000,000 to $175,000,000 and operating income of approximately $30,600,000 to $32,600,000, yielding operating margins of 18%, with incremental margins, ex-items, exceeding 50%.  The Company’s EPS for the third quarter of 2019, using an effective tax rate of 20%, is projected to be $0.48 to $0.52.  Core Lab’s third quarter 2019 guidance is based on projections for the underlying operations and excludes gains and losses in foreign exchange.

Earnings Call Scheduled

The Company has scheduled a conference call to discuss Core's second quarter 2019 earnings announcement. The call will begin at 7:30 a.m. CDT / 2:30 p.m. CEST on Thursday, 25 July 2019. To listen to the call, please go to Core's website at www.corelab.com.

Core Laboratories N.V. (www.corelab.com) is a leading provider of proprietary and patented reservoir description and production enhancement services and products used to optimize petroleum reservoir performance.  The Company has over 70 offices in more than 50 countries and is located in every major oil-producing province in the world. This release, as well as other statements we make, includes forward-looking statements regarding the future revenue, profitability, business strategies and developments of the Company made in reliance upon the safe harbor provisions of Federal securities law. The Company's outlook is subject to various important cautionary factors, including risks and uncertainties related to the oil and natural gas industry, business conditions, international markets, international political climates and other factors as more fully described in the Company's most recent Forms 10-K, 10-Q and 8-K filed with

 


 

or furnished to the Securities and Exchange Commission.  These important factors could cause the Company's actual results to differ materially from those described in these forward-looking statements. Such statements are based on current expectations of the Company's performance and are subject to a variety of factors, some of which are not under the control of the Company. Because the information herein is based solely on data currently available, and because it is subject to change as a result of changes in conditions over which the Company has no control or influence, such forward-looking statements should not be viewed as assurance regarding the Company's future performance. The Company undertakes no obligation to publicly update or revise any forward looking statement to reflect events or circumstances that may arise after the date of this press release, except as required by law.

Visit the Company's website at www.corelab.com. Connect with Core Lab on Facebook, LinkedIn and YouTube.

 

For more information, contact:

Gwen Schreffler - SVP Corporate Development and Investor Relations, +1 713 328 6210

 

 


 

CORE LABORATORIES N.V. & SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except per share data)

(Unaudited)

 

Three Months Ended

 

 

% Variance

 

 

 

 

June 30, 2019

 

 

March 31, 2019

 

 

June 30, 2018

 

 

vs. Q1-19

 

 

vs. Q2-18

 

 

REVENUE

 

$

169,038

 

 

$

169,194

 

 

$

175,475

 

 

(0.1)%

 

 

(3.7)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs of services and sales

 

 

124,451

 

 

 

127,383

 

 

 

123,773

 

 

(2.3)%

 

 

0.5%

 

 

General and administrative expense

 

 

9,801

 

 

 

17,437

 

 

 

12,202

 

 

(43.8)%

 

 

(19.7)%

 

 

Depreciation and amortization

 

 

5,786

 

 

 

5,587

 

 

 

5,868

 

 

3.6%

 

 

(1.4)%

 

 

Other (income) expense, net

 

 

992

 

 

 

2,373

 

 

 

183

 

 

NM

 

 

NM

 

 

Total operating expenses

 

 

141,030

 

 

 

152,780

 

 

 

142,026

 

 

(7.7)%

 

 

(0.7)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING INCOME

 

 

28,008

 

 

 

16,414

 

 

 

33,449

 

 

70.6%

 

 

(16.3)%

 

 

Interest expense

 

 

3,714

 

 

 

3,726

 

 

 

3,296

 

 

(0.3)%

 

 

12.7%

 

 

Income from continuing operations

   before income tax expense

 

 

24,294

 

 

 

12,688

 

 

 

30,153

 

 

91.5%

 

 

(19.4)%

 

 

Income tax expense (benefit)

 

 

4,808

 

 

 

(27,610

)

 

 

5,020

 

 

NM

 

 

(4.2)%

 

 

Income from continuing operations

 

 

19,486

 

 

 

40,298

 

 

 

25,133

 

 

(51.6)%

 

 

(22.5)%

 

 

Income (loss) from discontinued

   operations, net of income taxes

 

 

7,971

 

 

 

259

 

 

 

(328

)

 

NM

 

 

NM

 

 

Net income

 

 

27,457

 

 

 

40,557

 

 

 

24,805

 

 

(32.3)%

 

 

10.7%

 

 

Net income attributable to non-

   controlling interest

 

 

43

 

 

 

47

 

 

 

53

 

 

NM

 

 

NM

 

 

Net income attributable to Core

   Laboratories N.V.

 

$

27,414

 

 

$

40,510

 

 

$

24,752

 

 

(32.3)%

 

 

10.8%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted EPS from continuing

   operations

 

$

0.43

 

 

$

0.90

 

 

$

0.57

 

 

(52.2)%

 

 

(24.6)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted EPS attributable to Core

   Laboratories N.V.

 

$

0.61

 

 

$

0.91

 

 

$

0.56

 

 

(33.0)%

 

 

8.9%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average diluted common

   shares outstanding

 

 

44,815

 

 

 

44,734

 

 

 

44,493

 

 

0.2%

 

 

0.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effective tax rate

 

 

20

%

 

 

(218

)%

 

 

17

%

 

NM

 

 

NM

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SEGMENT INFORMATION:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reservoir Description

 

$

105,649

 

 

$

103,292

 

 

$

102,107

 

 

2.3%

 

 

3.5%

 

 

Production Enhancement

 

 

63,389

 

 

 

65,902

 

 

 

73,368

 

 

(3.8)%

 

 

(13.6)%

 

 

Total

 

$

169,038

 

 

$

169,194

 

 

$

175,475

 

 

(0.1)%

 

 

(3.7)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reservoir Description

 

$

15,878

 

 

$

6,179

 

 

$

14,760

 

 

157.0%

 

 

7.6%

 

 

Production Enhancement

 

 

10,424

 

 

 

9,912

 

 

 

18,427

 

 

5.2%

 

 

(43.4)%

 

 

Corporate and Other

 

 

1,706

 

 

 

323

 

 

 

262

 

 

NM

 

 

NM

 

 

Total

 

$

28,008

 

 

$

16,414

 

 

$

33,449

 

 

70.6%

 

 

(16.3)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

"NM" means not meaningful

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 

CORE LABORATORIES N.V. & SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(amounts in thousands, except per share data)

(Unaudited)

 

Six Months Ended

 

 

% Variance

 

 

 

 

June 30, 2019

 

 

June 30, 2018

 

 

 

 

 

 

REVENUE

 

$

338,232

 

 

$

345,493

 

 

(2.1)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING EXPENSES:

 

 

 

 

 

 

 

 

 

 

 

 

 

Costs of services and sales

 

 

251,834

 

 

 

243,091

 

 

3.6%

 

 

General and administrative expense

 

 

27,238

 

 

 

24,911

 

 

9.3%

 

 

Depreciation and amortization

 

 

11,373

 

 

 

11,686

 

 

(2.7)%

 

 

Other (income) expense, net

 

 

3,365

 

 

 

40

 

 

NM

 

 

Total operating expenses

 

 

293,810

 

 

 

279,728

 

 

5.0%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

OPERATING INCOME

 

 

44,422

 

 

 

65,765

 

 

(32.5)%

 

 

Interest expense

 

 

7,440

 

 

 

6,416

 

 

16.0%

 

 

Income from continuing operations before income tax expense

 

 

36,982

 

 

 

59,349

 

 

(37.7)%

 

 

Income tax expense (benefit)

 

 

(22,802

)

 

 

10,293

 

 

NM

 

 

Income from continuing operations

 

 

59,784

 

 

 

49,056

 

 

21.9%

 

 

Income (loss) from discontinued operations, net of income taxes

 

 

8,230

 

 

 

(674

)

 

NM

 

 

Net income

 

 

68,014

 

 

 

48,382

 

 

40.6%

 

 

Net income attributable to non-controlling interest

 

 

90

 

 

 

103

 

 

NM

 

 

Net income attributable to Core Laboratories N.V.

 

$

67,924

 

 

$

48,279

 

 

40.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted EPS from continuing operations

 

$

1.33

 

 

$

1.10

 

 

20.9%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted EPS attributable to Core Laboratories N.V.

 

$

1.51

 

 

$

1.08

 

 

39.8%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average diluted common shares outstanding

 

 

44,848

 

 

 

44,515

 

 

0.7%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Effective tax rate

 

 

(62

)%

 

 

17

%

 

NM

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SEGMENT INFORMATION:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

Reservoir Description

 

$

208,941

 

 

$

202,916

 

 

3.0%

 

 

Production Enhancement

 

 

129,291

 

 

 

142,577

 

 

(9.3)%

 

 

Total

 

$

338,232

 

 

$

345,493

 

 

(2.1)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Operating income:

 

 

 

 

 

 

 

 

 

 

 

 

 

Reservoir Description

 

$

22,057

 

 

$

29,517

 

 

(25.3)%

 

 

Production Enhancement

 

 

20,336

 

 

 

36,114

 

 

(43.7)%

 

 

Corporate and Other

 

 

2,029

 

 

 

134

 

 

NM

 

 

Total

 

$

44,422

 

 

$

65,765

 

 

(32.5)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

"NM" means not meaningful

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


 


 

CORE LABORATORIES N.V. & SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEET

(amounts in thousands)

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

% Variance

 

 

ASSETS:

 

June 30, 2019

 

 

March 31, 2019

 

 

June 30, 2018

 

 

vs. Q1-19

 

 

vs. Q2-18

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

12,546

 

 

$

13,206

 

 

$

13,021

 

 

(5.0)%

 

 

(3.6)%

 

 

Accounts receivable, net

 

 

134,900

 

 

 

132,859

 

 

 

136,148

 

 

1.5%

 

 

(0.9)%

 

 

Inventory

 

 

49,311

 

 

 

50,147

 

 

 

39,855

 

 

(1.7)%

 

 

23.7%

 

 

Other current assets

 

 

28,476

 

 

 

40,211

 

 

 

36,638

 

 

(29.2)%

 

 

(22.3)%

 

 

Total Current Assets

 

 

225,233

 

 

 

236,423

 

 

 

225,662

 

 

(4.7)%

 

 

(0.2)%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Property, plant and equipment, net

 

 

125,699

 

 

 

124,758

 

 

 

122,787

 

 

0.8%

 

 

2.4%

 

 

Right-of-use assets

 

 

76,290

 

 

 

77,537

 

 

 

 

 

(1.6)%

 

 

NM

 

 

Intangibles, goodwill and other long-term assets, net

 

 

354,296

 

 

 

353,042

 

 

 

256,295

 

 

0.4%

 

 

38.2%

 

 

Total assets

 

$

781,518

 

 

$

791,760

 

 

$

604,744

 

 

(1.3)%

 

 

29.2%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

LIABILITIES AND EQUITY:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts payable

 

$

41,995

 

 

$

44,467

 

 

$

45,278

 

 

(5.6)%

 

 

(7.3)%

 

 

Short-term operating lease obligations

 

 

12,968

 

 

 

13,003

 

 

 

 

 

(0.3)%

 

 

NM

 

 

Other current liabilities

 

 

69,863

 

 

 

71,145

 

 

 

55,313

 

 

(1.8)%

 

 

26.3%

 

 

Total current liabilities

 

 

124,826

 

 

 

128,615

 

 

 

100,591

 

 

(2.9)%

 

 

24.1%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Long-term debt, net

 

 

290,022

 

 

 

294,896

 

 

 

241,687

 

 

(1.7)%

 

 

20.0%

 

 

Long-term operating lease obligations

 

 

62,737

 

 

 

64,090

 

 

 

 

 

(2.1)%

 

 

NM

 

 

Other long-term liabilities

 

 

111,441

 

 

 

116,806

 

 

 

104,692

 

 

(4.6)%

 

 

6.4%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total equity

 

 

192,492

 

 

 

187,353

 

 

 

157,774

 

 

2.7%

 

 

22.0%

 

 

Total liabilities and equity

 

$

781,518

 

 

$

791,760

 

 

$

604,744

 

 

(1.3)%

 

 

29.2%

 

 

 


 


 

CORE LABORATORIES N.V. & SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)

(Unaudited)

 

Three Months Ended

 

 

 

 

June 30, 2019

 

 

March 31, 2019

 

 

June 30, 2018

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

19,486

 

 

$

40,298

 

 

$

25,133

 

 

Income (loss) from discontinued operations

 

 

7,971

 

 

 

259

 

 

 

(328

)

 

Net Income

 

$

27,457

 

 

$

40,557

 

 

$

24,805

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

3,245

 

 

 

11,096

 

 

 

6,101

 

 

Depreciation and amortization

 

 

5,786

 

 

 

5,587

 

 

 

5,810

 

 

Deferred income tax

 

 

(3,356

)

 

 

(31,760

)

 

 

653

 

 

Gain on sale of business

 

 

(1,154

)

 

 

 

 

 

 

 

Gain on sale of discontinued operations

 

 

(8,808

)

 

 

 

 

 

 

 

Accounts receivable

 

 

(2,385

)

 

 

(3,936

)

 

 

488

 

 

Inventory

 

 

1,492

 

 

 

(4,407

)

 

 

(3,427

)

 

Accounts payable

 

 

(399

)

 

 

1,346

 

 

 

806

 

 

Other adjustments to net income

 

 

(4,798

)

 

 

6,673

 

 

 

(8,246

)

 

Net cash provided by operating activities

 

$

17,080

 

 

$

25,156

 

 

$

26,990

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

Capital expenditures

 

$

(7,047

)

 

$

(5,183

)

 

$

(7,472

)

 

Proceeds from sale of business

 

 

2,980

 

 

 

 

 

 

 

 

Proceeds from sale of discontinued operations

 

 

16,642

 

 

 

 

 

 

 

 

Other investing activities

 

 

(316

)

 

 

(22

)

 

 

(1,226

)

 

Net cash provided by (used in) investing activities

 

$

12,259

 

 

$

(5,205

)

 

$

(8,698

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

 

 

 

 

 

Repayment of debt borrowings

 

$

(36,000

)

 

$

(32,000

)

 

$

(28,000

)

 

Proceeds from debt borrowings

 

 

31,000

 

 

 

37,000

 

 

 

36,000

 

 

Dividends paid

 

 

(24,395

)

 

 

(24,374

)

 

 

(24,313

)

 

Repurchase of treasury shares

 

 

(604

)

 

 

(487

)

 

 

(650

)

 

Other financing activities

 

 

 

 

 

 

 

 

(1,552

)

 

Net cash used in financing activities

 

$

(29,999

)

 

$

(19,861

)

 

$

(18,515

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

(660

)

 

 

90

 

 

 

(223

)

 

CASH AND CASH EQUIVALENTS, beginning of period

 

 

13,206

 

 

 

13,116

 

 

 

13,244

 

 

CASH AND CASH EQUIVALENTS, end of period

 

$

12,546

 

 

$

13,206

 

 

$

13,021

 

 

 


 


 

CORE LABORATORIES N.V. & SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(amounts in thousands)

(Unaudited)

 

 

Six Months Ended

 

 

 

 

June 30, 2019

 

 

June 30, 2018

 

 

CASH FLOWS FROM OPERATING ACTIVITIES

 

 

 

 

 

 

 

 

 

Income from continuing operations

 

$

59,784

 

 

$

49,056

 

 

Income (loss) from discontinued operations

 

 

8,230

 

 

 

(674

)

 

Net Income

 

$

68,014

 

 

$

48,382

 

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

 

 

Stock-based compensation

 

 

14,341

 

 

 

12,392

 

 

Depreciation and amortization

 

 

11,373

 

 

 

11,686

 

 

Deferred income tax

 

 

(35,116

)

 

 

397

 

 

Gain on sale of business

 

 

(1,154

)

 

 

 

 

Gain on sale of discontinued operations

 

 

(8,808

)

 

 

 

 

Accounts receivable

 

 

(6,321

)

 

 

(5,425

)

 

Inventory

 

 

(2,915

)

 

 

(7,113

)

 

Accounts payable

 

 

947

 

 

 

3,440

 

 

Other adjustments to net income

 

 

1,875

 

 

 

(13,676

)

 

Net cash provided by operating activities

 

$

42,236

 

 

$

50,083

 

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM INVESTING ACTIVITIES

 

 

 

 

 

 

 

 

 

Capital expenditures

 

$

(12,230

)

 

$

(11,915

)

 

Proceeds from sale of business

 

 

2,980

 

 

 

 

 

Proceeds from sale of discontinued operations

 

 

16,642

 

 

 

 

 

Other investing activities

 

 

(338

)

 

 

(1,399

)

 

Net cash provided by (used in) investing activities

 

$

7,054

 

 

$

(13,314

)

 

 

 

 

 

 

 

 

 

 

 

CASH FLOWS FROM FINANCING ACTIVITIES

 

 

 

 

 

 

 

 

 

Repayment of debt borrowings

 

$

(68,000

)

 

$

(57,000

)

 

Proceeds from debt borrowings

 

 

68,000

 

 

 

73,000

 

 

Dividends paid

 

 

(48,769

)

 

 

(48,635

)

 

Repurchase of treasury shares

 

 

(1,091

)

 

 

(3,960

)

 

Other financing activities

 

 

 

 

 

(1,553

)

 

Net cash used in financing activities

 

$

(49,860

)

 

$

(38,148

)

 

 

 

 

 

 

 

 

 

 

 

NET CHANGE IN CASH AND CASH EQUIVALENTS

 

 

(570

)

 

 

(1,379

)

 

CASH AND CASH EQUIVALENTS, beginning of period

 

 

13,116

 

 

 

14,400

 

 

CASH AND CASH EQUIVALENTS, end of period

 

$

12,546

 

 

$

13,021

 

 

 

 


 


 

Non-GAAP Information

 

Management believes that the exclusion of certain income and expenses enables it to evaluate more effectively the Company's operations period-over-period and to identify operating trends that could otherwise be masked by the excluded Items.  For this reason, we use certain non-GAAP measures that exclude these Items; and we feel that this presentation provides a clearer comparison with the results reported in prior periods.  The non-GAAP financial measures should be considered in addition to, and not as a substitute for, the financial results prepared in accordance with GAAP, as more fully discussed in the Company's financial statement and filings with the Securities and Exchange Commission.

 

Reconciliation of Operating Income, Income from Continuing Operations and Earnings Per Diluted Share from Continuing Operations

(amounts in thousands, except per share data)

(Unaudited)

 

 

Operating Income from Continuing Operations

 

 

 

Three Months Ended

 

 

 

June 30, 2019

 

 

March 31, 2019

 

 

June 30, 2018

 

GAAP reported

 

$

28,008

 

 

$

16,414

 

 

$

33,449

 

Stock compensation and employment related charges 1

 

 

 

 

 

10,403

 

 

 

 

Cost reduction and other charges

 

 

2,977

 

 

 

 

 

 

 

Gain on sale of business

 

 

(1,154

)

 

 

 

 

 

 

Foreign exchange losses

 

 

(218

)

 

 

37

 

 

 

654

 

Excluding specific items

 

$

29,613

 

 

$

26,854

 

 

$

34,103

 

 

 

 

 

 

Income from Continuing Operations

 

 

 

Three Months Ended

 

 

 

June 30, 2019

 

 

March 31, 2019

 

 

June 30, 2018

 

GAAP reported

 

$

19,486

 

 

$

40,298

 

 

$

25,133

 

Stock compensation and employment related charges 1

 

 

 

 

 

9,731

 

 

 

 

Cost reduction and other charges

 

 

2,381

 

 

 

 

 

 

 

Gain on sale of business

 

 

(1,154

)

 

 

 

 

 

 

Foreign exchange losses

 

 

(174

)

 

 

31

 

 

 

545

 

Impact of higher/lower tax rate 2 3

 

 

181

 

 

 

(30,402

)

 

 

508

 

Excluding specific items

 

$

20,720

 

 

$

19,658

 

 

$

26,186

 

 

 

 

 

Earnings Per Diluted Share from Continuing Operations

 

 

 

Three Months Ended

 

 

 

June 30, 2019

 

 

March 31, 2019

 

 

June 30, 2018

 

GAAP reported

 

$

0.43

 

 

$

0.90

 

 

$

0.57

 

Stock compensation and employment related charges 1

 

 

-

 

 

 

0.22

 

 

 

-

 

Cost reduction and other charges

 

 

0.06

 

 

 

-

 

 

 

-

 

Gain on sale of business

 

 

(0.03

)

 

 

-

 

 

 

-

 

Foreign exchange losses

 

 

-

 

 

 

-

 

 

 

0.01

 

Impact of higher/lower tax rate 2 3

 

 

-

 

 

 

(0.68

)

 

 

0.01

 

Excluding specific items

 

$

0.46

 

 

$

0.44

 

 

$

0.59

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Stock compensation expense recognized pursuant to FASB ASC 718 "Stock Compensation" associated with executives

       reaching eligible retirement age and charge associated with settlement of employment related claim.

 

(2) 2019 Quarter 1 includes a tax benefit resulting from a corporate restructuring, net of withholding taxes on unremitted earnings from

      subsidiaries and stock compensation expense which is nondeductible in the U.S.

 

(3) 2019 Quarter 2 includes adjustments to reflect tax expense at a normalized rate of 20%. 2019 Quarter 1 and 2018 Quarter 2 includes

       adjustments to reflect tax expense at a normalized rate of 15%.

 

 

 


 

Segment Information

(amounts in thousands)

(Unaudited)

 

 

Operating Income from Continuing Operations

 

 

 

Three Months Ended June 30, 2019

 

 

 

Reservoir Description

 

 

Production Enhancement

 

 

Corporate and Other

 

GAAP reported

 

$

15,878

 

 

$

10,424

 

 

$

1,706

 

Foreign exchange losses

 

 

436

 

 

 

131

 

 

 

(785

)

Cost reduction and other charges

 

 

1,907

 

 

 

1,070

 

 

 

 

Gain on sale of business

 

 

 

 

 

 

 

 

(1,154

)

Excluding specific items

 

$

18,221

 

 

$

11,625

 

 

$

(233

)

 

 

Return on Invested Capital

 

Return on Invested Capital ("ROIC") is based on Bloomberg's calculation on the trailing four quarters from the most recently reported quarter and the balance sheet of the most recent reported quarter, and is presented based on our belief that this non-GAAP measure is useful information to investors and management when comparing our profitability and the efficiency with which we have employed capital over time relative to other companies. ROIC is not a measure of financial performance under GAAP and should not be considered as an alternative to net income.

 

ROIC of 21.3% is defined by Bloomberg as Net Operating Profit ("NOP") of $104 million plus Cash Operating Tax Benefit ("COT") of $9 million divided by Total Invested Capital ("TIC") of $529 million, where NOP is defined as GAAP net income before minority interest plus the sum of income tax expense, interest expense, and pension expense less pension service cost and COT is defined as income tax expense plus the sum of the change in net deferred taxes, and the tax effect on interest expense and TIC is defined as GAAP stockholder's equity plus the sum of net long-term debt, allowance for doubtful accounts, net balance of deferred taxes, income tax payable, and other charges.

 

Free Cash Flow

 

Core uses the non-GAAP measure of free cash flow to evaluate its cash flows and results of operations. Free cash flow is an important measurement because it represents the cash from operations, in excess of capital expenditures, available to operate the business and fund non-discretionary obligations. Free cash flow is not a measure of operating performance under GAAP, and should not be considered in isolation nor construed as an alternative consideration to operating income, net income, earnings per share, or cash flows from operating, investing, or financing activities, each as determined in accordance with GAAP.  Free cash flow should not be considered a measure of liquidity. Moreover, since free cash flow is not a measure determined in accordance with GAAP and thus is susceptible to varying interpretations and calculations, free cash flow as presented may not be comparable to similarly titled measures presented by other companies.

 

 

 

 

 

 

 


Computation of Free Cash Flow

(amounts in thousands)

(Unaudited)

 

Three Months Ended

 

 

Six Months Ended

 

 

 

 

June 30, 2019

 

 

June 30, 2019

 

 

Net cash provided by operating activities

 

$

17,080

 

 

$

42,236

 

 

Capital expenditures

 

 

(7,047

)

 

 

(12,230

)

 

Free cash flow

 

$

10,033

 

 

$

30,006

 

 

 

 

 

 

###